Plasma levels of cyclic GMP, immune parameters and depressive status during interferon therapy. A prospective study in Japan.
In this report, we investigated the relationship between depressive symptoms and plasma interferon (IFN)-alpha-like immunoreactivity, cyclic GMP (cGMP) and soluble interleukin-2 receptor (sIL-2R) levels during IFN therapy. An altered mood state was observed in 5 of 26 patients. IFN-alpha-like immunoreactivity in the depressed group tended to be elevated. cGMP levels of depressed patients were significantly greater than those of control subjects before and 6 weeks after IFN therapy. However, sIL-2R levels were not different between the two groups. These results suggest that a number of patients suffered from depression during IFN therapy and that patients had greater concentrations of cGMP levels.
Kagaya
A
A
Department of Psychiatry and Neurosciences, Hiroshima Univeristy School of Medicine, Japan.
Uchitomi
Y
Y
Takezaki
E
E
Fukue
M
M
Tsukano
K
K
Kugaya
A
A
Minagawa
H
H
Takebayashi
M
M
Zensho
H
H
Oyamada
T
T
Yamawaki
S
S
D000368:Aged; D006152:Cyclic GMP / Q000097:blood*; D003866:Depressive Disorder / Q000139:chemically induced* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007372:Interferons / Q000009:adverse effects*; D007564:Japan; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D007372:Interferons; D006152:Cyclic GMP